Literature DB >> 22452384

Developing standards of care for HIV prevention research in developing countries -- a case study of 10 research centers in Eastern and Southern Africa.

Prince Bahati Ngongo1, Frances Priddy, Harriet Park, Julie Becker, Bonnie Bender, Pat Fast, Omu Anzala, Gaudensia Mutua, Eugene Ruzagira, Anatoli Kamali, Etienne Karita, Peter Mugo, Elwyn Chomba, Linda-Gail Bekker, Surita Roux, Annet Nanvubya, Tsedal Mebrahtu.   

Abstract

Standards of care provided to volunteers in HIV prevention research in developing countries are evolving. Inconsistency in standards, particularly within a research network highlights the need to balance volunteers' health and wellness with the efficient conduct of research. Ten research centers (RC's) in East and Southern Africa affiliated with the International AIDS Vaccine Initiative (IAVI) were studied using a mixed methods approach to understand variations, similarities and gaps in services provided, recipients of services, referral systems, and barriers to referral uptake. These data were then used to develop expected standards across the 10 RCs. Findings indicated that RCs consistently provided HIV risk reduction and family planning (FP) counseling, male condoms, management of sexually transmitted infections, CD-4 counts, and general medical care to volunteers and non-research volunteers. Services that were less consistently provided on-site included: female condoms, adult male circumcision (AMC), antiretroviral therapy (ART) and post-exposure prophylaxis (PEP) in case of rape. The FP options provided on-site varied, with few providing implants, intrauterine devices, tubal ligation, and vasectomy. Most RCs had established referral systems for ART, AMC, PEP, and FP, but few had referral points for psychosocial services. Few RCs had comprehensive guidelines on referrals other than those related to adverse events. Findings indicate that the greatest challenges for referral uptake were transportation and health care costs, poor quality and inconsistency of services at some referral points. Few RCs covered the cost of referrals for non-study related adverse events. A collaborative process between IAVI and the RCs was undertaken to reach consensus on expected standards of care. A set of required and recommended services to be provided on-site or by referral was developed. In developing such standards, we tried to balance scientific priorities, equity, contextual realities, community expectations, and cost-effectiveness.

Entities:  

Mesh:

Year:  2012        PMID: 22452384     DOI: 10.1080/09540121.2012.656572

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  13 in total

1.  Dynamics and Correlates of CD8 T-Cell Counts in Africans with Primary Human Immunodeficiency Virus Type 1 Infection.

Authors:  Heather A Prentice; Hailin Lu; Matthew A Price; Anatoli Kamali; Etienne Karita; Shabir Lakhi; Eduard J Sanders; Omu Anzala; Susan Allen; Paul A Goepfert; Eric Hunter; Jill Gilmour; Jianming Tang
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

2.  Challenges and impact of conducting vaccine trials in Asia and Africa: New Technologies in Emerging Markets, October 16th-18th 2012; World Vaccine Congress, Lyon.

Authors:  Sonali Kochhar
Journal:  Hum Vaccin Immunother       Date:  2013-01-15       Impact factor: 3.452

3.  Dynamics of viremia in primary HIV-1 infection in Africans: insights from analyses of host and viral correlates.

Authors:  Heather A Prentice; Matthew A Price; Travis R Porter; Emmanuel Cormier; Michael J Mugavero; Anatoli Kamali; Etienne Karita; Shabir Lakhi; Eduard J Sanders; Omu Anzala; Pauli N Amornkul; Susan Allen; Eric Hunter; Richard A Kaslow; Jill Gilmour; Jianming Tang
Journal:  Virology       Date:  2013-12-12       Impact factor: 3.616

4.  Immunogenetic factors in early immune control of human immunodeficiency virus type 1 (HIV-1) infection: Evaluation of HLA class I amino acid variants in two African populations.

Authors:  Howard W Wiener; Sadeep Shrestha; Hailin Lu; Etienne Karita; William Kilembe; Susan Allen; Eric Hunter; Paul A Goepfert; Jianming Tang
Journal:  Hum Immunol       Date:  2017-12-28       Impact factor: 2.850

5.  Ancillary care in South African HIV vaccine trials: addressing needs, drafting protocols, and engaging community.

Authors:  Catherine M Slack
Journal:  J Empir Res Hum Res Ethics       Date:  2014-02       Impact factor: 1.742

6.  HLA-B*57 versus HLA-B*81 in HIV-1 infection: slow and steady wins the race?

Authors:  Heather A Prentice; Travis R Porter; Matthew A Price; Emmanuel Cormier; Dongning He; Paul K Farmer; Anatoli Kamali; Etienne Karita; Shabir Lakhi; Eduard J Sanders; Omu Anzala; Pauli N Amornkul; Susan Allen; Eric Hunter; Richard A Kaslow; Jill Gilmour; Jianming Tang
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

7.  CD4:CD8 lymphocyte ratio as a quantitative measure of immunologic health in HIV-1 infection: findings from an African cohort with prospective data.

Authors:  Jianming Tang; Xuelin Li; Matthew A Price; Eduard J Sanders; Omu Anzala; Etienne Karita; Anatoli Kamali; Shabir Lakhi; Susan Allen; Eric Hunter; Richard A Kaslow; Jill Gilmour
Journal:  Front Microbiol       Date:  2015-07-01       Impact factor: 5.640

8.  Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa.

Authors:  Pauli N Amornkul; Etienne Karita; Anatoli Kamali; Wasima N Rida; Eduard J Sanders; Shabir Lakhi; Matt A Price; William Kilembe; Emmanuel Cormier; Omu Anzala; Mary H Latka; Linda-Gail Bekker; Susan A Allen; Jill Gilmour; Patricia E Fast
Journal:  AIDS       Date:  2013-11-13       Impact factor: 4.177

9.  Ensuring Access to HIV Prevention Services in South African HIV Vaccine Trials: Correspondence Between Guidelines and Practices.

Authors:  Zaynab Essack
Journal:  Public Health Ethics       Date:  2014-07       Impact factor: 1.940

10.  Improving ethical and participatory practice for marginalized populations in biomedical HIV prevention trials: lessons from Thailand.

Authors:  Dan Allman; Melissa Hope Ditmore; Karyn Kaplan
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.